Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. the Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy) by Pezzini, Alessandro et al.
RESEARCH PAPER
Serum cholesterol levels, HMG-CoA reductase
inhibitors and the risk of intracerebral haemorrhage.
The Multicenter Study on Cerebral Haemorrhage
in Italy (MUCH-Italy)
Alessandro Pezzini,1 Mario Grassi,2 Licia Iacoviello,3 Marialuisa Zedde,4
Simona Marcheselli,5 Giorgio Silvestrelli,6 Maria Luisa DeLodovici,7 Maria Sessa,8
Andrea Zini,9 Maurizio Paciaroni,10 Cristiano Azzini,11 Massimo Gamba,12
Massimo Del Sette,13 Antonella Toriello,14 Carlo Gandolfo,15
Domenico Marco Bonifati,16 Rossana Tassi,17 Anna Cavallini,18 Alberto Chiti,19
Rocco Salvatore Calabrò,20 Rossella Musolino,21 Paolo Bovi,22 Giampaolo Tomelleri,22
Augusto Di Castelnuovo,3 Laura Vandelli,9 Marco Ritelli,23 Giancarlo Agnelli,10
Alessandro De Vito,11 Nicola Pugliese,14 Giuseppe Martini,17 Alessia Lanari,6
Alfonso Ciccone,6 Corrado Lodigiani,24 Giovanni Malferrari,4 Elisabetta Del Zotto,25
Andrea Morotti,1 Paolo Costa,1 Loris Poli,1 Valeria De Giuli,1 Silvia Bonaiti,1
Paolo La Spina,21 Norina Marcello,4 Giuseppe Micieli,18 Giovanni de Gaetano,3
Marina Colombi,23 Alessandro Padovani,1 on behalf of the Multicenter Study on
Cerebral Haemorrhage in Italy (MUCH-Italy) Investigators
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2015-312736).
For numbered afﬁliations see
end of article.
Correspondence to
Dr Alessandro Pezzini,
Dipartimento di Scienze
Cliniche e Sperimentali, Clinica
Neurologica, Università degli
Studi di Brescia, P le Spedali
Civili 1, Brescia 25123, Italia;
ale_pezzini@hotmail.com
Received 19 November 2015
Revised 29 February 2016
Accepted 4 March 2016
Published Online First
21 March 2016
To cite: Pezzini A,
Grassi M, Iacoviello L, et al.
J Neurol Neurosurg
Psychiatry 2016;87:
924–929.
ABSTRACT
Objective Although a concern exists that 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors (statins)
might increase the risk of intracerebral haemorrhage
(ICH), the contribution of these agents to the
relationship between serum cholesterol and disease
occurrence has been poorly investigated.
Methods We compared consecutive patients having ICH
with age and sex-matched stroke-free control subjects in a
case–control analysis, as part of the Multicenter Study on
Cerebral Haemorrhage in Italy (MUCH-Italy), and tested
the presence of interaction effects between total serum
cholesterol levels and statins on the risk of ICH.
Results A total of 3492 cases (mean age, 73.0
±12.7 years; males, 56.6%) and 3492 control subjects
were enrolled. Increasing total serum cholesterol levels
were conﬁrmed to be inversely associated with ICH. We
observed a statistical interaction between total serum
cholesterol levels and statin use for the risk of haemorrhage
(Interaction OR (IOR), 1.09; 95% CI 1.05 to 1.12).
Increasing levels of total serum cholesterol were associated
with a decreased risk of ICH within statin strata (average
OR, 0.87; 95% CI 0.86 to 0.88 for every increase of
0.26 mmol/l of total serum cholesterol concentrations),
while statin use was associated with an increased risk (OR,
1.54; 95% CI 1.31 to 1.81 of the average level of total
serum cholesterol). The protective effect of serum
cholesterol against ICH was reduced by statins in strictly
lobar brain regions more than in non-lobar ones.
Conclusions Statin therapy and total serum cholesterol
levels exhibit interaction effects towards the risk of ICH. The
magnitude of such effects appears higher in lobar brain
regions.
INTRODUCTION
Increasing evidence has suggested that serum
cholesterol is inversely associated with the risk of
intracerebral haemorrhage (ICH).1 In recent
years, 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors, or statins, have
emerged as the most important class of cholesterol-
lowering agents and among the most commonly
prescribed drugs worldwide.2 In spite of the
proven beneﬁts of statins in reducing the risk of
cardiovascular and cerebrovascular disease, the
results of several studies have raised concerns about
the risk of haemorrhagic stroke, mainly ICH, in
people treated with these agents,3 4 which is pre-
sumed to be the consequence of decreased serum
cholesterol concentrations. Some of the pleiotropic
effects of statins, including decreased platelet aggre-
gation and decreased thrombogenesis, could
further increase the risk of cerebral bleeding.5
Although this potential risk, if any, is likely to be
overshadowed by the large beneﬁts in terms of
reduction of individual susceptibility to cardiovas-
cular disease, the clinical implications could be rele-
vant, and clinicians should be asked to carefully
consider this relation when prescribing statin
therapy targeting low cholesterol goals. So far, the
contribution of these agents to the link between
serum cholesterol and ICH has been poorly investi-
gated and the existing reports conﬂict with one
another. Therefore, in the present study, we aimed
at elucidating whether (1) there is a relationship
between statin therapy and serum cholesterol, or
vice versa, towards the risk of intracerebral bleeding
and (2) such a relationship might vary according to
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the presumed mechanism of cerebral haemorrhage, in a cohort
of Italian patients with ICH.
MATERIAL AND METHODS
Study group and design
The Multicenter Study on Cerebral Haemorrhage in Italy
(MUCH-Italy) is a countrywide network of neurological centres
designed to investigate epidemiology, risk factors and conse-
quences of ICH in the setting of a hospital-based, multicentre,
prospectively-recruiting, observational study, coordinated by the
University of Brescia.6 The MUCH-Italy study consists also of a
biostatistical core (University of Pavia) and 19 Italian clinical
recruiting centres. The institutional review board at each partici-
pating study centre provided approval for the study. Written
informed consent was obtained from all participants (or next of
kin). For the purpose of the present analysis, we screened data
sets from patients with acute ICH consecutively admitted from
1 January 2002 to 31 July 2014.
Cases
Criteria for patient selection, risk factor deﬁnition, diagnostic
procedures and assessment of haematoma location have been
previously described.6 Brieﬂy, eligibility for study participation
required neuroimaging (CT or MRI) conﬁrmation of haemor-
rhagic stroke. Exclusion criteria included the presence of
trauma, brain tumour, haemorrhagic transformation of a cere-
bral infarction, vascular malformation or any other perceived
cause of secondary ICH. ICH location was assigned based on
admission CT scan by stroke neurologists at each participating
centre. ICH isolated to the cortex (with or without involvement
of subcortical white matter) and cerebellar haematomas were
deﬁned as lobar ICH, while ICH selectively involving the thal-
amus, basal ganglia or brainstem was deﬁned as deep (non-
lobar) ICH. Multiple concurrent bleeds involving deep and
lobar territories were deﬁned as mixed ICH and represented an
exclusion criterion.
Control subjects
Control subjects were enrolled from the Moli-Sani project, an
Italian population-based study recruiting citizens of the Molise
region, an area between the Central and Southern regions,
aimed at investigating the equilibrium between genetics and
environment in the pathogenesis of cardiovascular, cerebrovas-
cular and cancer disease.7 Individuals included were matched
with cases by sex and age (±5 years), and were conﬁrmed to
have no medical history of stroke through interview and review
of medical records.
Risk factor deﬁnition
A history of vascular risk factors was deﬁned as the presence of
these predisposing conditions, either in the personal medical
history for both cases and control subjects or when identiﬁed
during admission for patients with ICH. In particular, smoking
was deﬁned as currently smoking one or more cigarettes per day
on a regular basis. Hypertension was deﬁned as systolic blood
pressure, BP >140 mm Hg and/or diastolic BP >90 mm Hg of
the acute phase, or using pharmacological treatment for hyper-
tension. Diabetes was deﬁned as fasting glucose levels
>6.9 mmol/L of the acute phase or current treatment with anti-
diabetic drugs. Based on daily alcohol consumption, participants
were dichotomised into excessive drinkers (>45 g of alcohol)
and light-moderate drinkers or non-drinkers. We also collected
information on atrial ﬁbrillation (medical history or electrocar-
diographic ﬁndings at admission), atherosclerotic peripheral
arterial disease (medical history), coronary artery disease
(medical history of angina, myocardial infarction, coronary
artery bypass graft or percutaneous transluminal coronary angio-
plasty), history of previous stroke or transient ischaemic attack
(based on clinical history) and pre-ICH medications (warfarin,
aspirin or other antiplatelet agents, antihypertensive agents, oral
hypoglycaemic agents or insulin and statins).
Measurement of serum lipid levels
Fasting lipids measurements were carried out on venous blood
samples in each participating centre, using comparable enzym-
atic procedures. Admission total serum cholesterol levels were
used for interaction analysis, while hypercholesterolaemia was
deﬁned as total serum cholesterol levels >6.2 mmol/L of the
acute phase or using pharmacological treatment to lower blood
lipids. Statin use included any of the following: atorvastatin, ﬂu-
vastatin, lovastatin, pravastatin, rosuvastatin or simvastatin, or a
combination of medications that included a statin. Current use
of these cholesterol-lowering medications was deﬁned as ﬁlling
a prescription for such medications in the 6 months prior to the
index date. Participants were classiﬁed as non-
hypercholesterolaemic, hypercholesterolaemic under treatment
with statins, or hypercholesterolemic not under treatment with
statins. Data were obtained from interviews with patients, next
of kin and/or attending physicians or general practitioners.
Statistical analyses
We compared the characteristics of patients with ICH and
control subjects, using the χ2 test for categorical variables, and
the independent-samples t test for continuous variables. Despite
the matching criteria adopted for the selection of control indivi-
duals, this group was, on average, 3 years younger than cases.
All multivariable analyses were, therefore, adjusted for age. We
performed unconditional logistic regression models to examine
the effect of selected risk factors in the prediction of disease
status (case/control) in each of the three study subgroups
(overall ICH, deep ICH and lobar ICH). In particular, we
adjusted for those variables that might potentially inﬂuence the
risk of cerebral bleeding, including age, hypertension (yes/no),
diabetes mellitus (yes/no), hypercholesterolaemia (yes/no),
current smoking (yes/no), daily alcohol intake (heavy drinkers/
light-moderate drinkers or non-drinkers) and antithrombotic
medications use (yes/no). As statin treatment might modify the
association between total serum cholesterol levels and ICH, we
investigated whether this relationship differed across strata of
statin use, and tested the presence of interaction or modiﬁcation
effects. The modelling strategy assumed disease status (case/
control) as outcome variable (Y), and total serum cholesterol
concentrations (X) and statin use (Z) as predictors. In particular,
we tested all the possible total serum cholesterol-statin use inter-
action logistic regression models (see online supplementary
ﬁgure S1). The assessment of interaction models was performed
without and with adjustment for the following covariates: age,
systolic BP values, serum glucose levels, smoking habit, daily
alcohol intake and use of antiplatelet agents and oral anticoagu-
lants. To compare these competing models, we computed the
Akaike’ Information Criterion (AIC=−2×model log-likelihood
+2×number of model parameters) and the Bayesian
Information Criterion (BIC=−2×model log-likelihood+log
(n)×number of model parameters). The selected model was the
one minimising either AIC or BIC.8 The regression parameter
estimates were re-expressed as ORs and Interaction ORs
(IOR=OR(group1)/OR(group2)), and 95% CIs. For visualising
main effects and interaction of total serum cholesterol levels (X)
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Table 1 Baseline demographics and clinical characteristics of the MUCH-Italy study group according to haemorrhage location
All ICH Lobar ICH Deep ICH
Cases
(n=3492)
Control
subjects
(n=3492) p Value
Cases
(n=1604)
Control
subjects
(n=1604) p Value
Cases
(n=1888)
Control
subjects
(n=1888) p Value
Age, years±SD 73.0± 12.7 70.6± 10.5 <0.001 73.9± 12.5 71.3±10.4 <0.001 72.3±12.7 70.0±10.6 <0.001
Sex, Male 1978 (56.6) 1978 (56.6) 872 (54.4) 872 (54.4) 1106 (58.6) 1106 (58.6)
Coronary artery disease 575 (16.5) 272 (7.8) <0.001 294 (18.4) 126 (8.0) <0.001 283 (15.0) 146 (7.8) <0.001
Previous atrial fibrillation 491 (14.1) 74 (2.1) <0.001 251 (15.7) 34 (2.1) <0.001 240 (12.7) 40 (2.1) <0.001
Previous stroke or TIA 553 (15.8) 268 (16.8) 285 (15.1)
Peripheral arterial disease 220 (6.3) 118 (7.4) 102 (5.4)
Hypertension <0.001 <0.001 <0.001
Non-hypertensive 861 (24.7) 1574 (45.1) 430 (26.8) 707 (44.1) 431 (22.9) 867 (45.9)
Hypertensive under treatment 2166 (62.1) 1822 (52.2) 998 (62.3) 852 (53.1) 1168 (62.0) 970 (51.4)
Hypertensive not under
treatment
460 (13.2) 96 (2.7) 175 (10.9) 45 (2.8) 285 (15.1) 51 (2.7)
Systolic blood pressure, mm Hg 165.6± 29.8 152.9±21.6 <0.001 161.6±28.8 152.8±21.5 <0.001 169.2±29.8 153.0±21.7 <0.001
Diastolic blood pressure, mm Hg 89.7±18.4 81.6±9.9 <0.001 87.0±17.6 81.1±10.1 <0.001 92.0±18.3 81.9±9.7 <0.001
Diabetes <0.001 <0.001
Non-diabetic 2846 (81.6) 3069 (87.8) 1327 (82.8) 1417 (88.4) 1519 (80.6) 1652 (87.5)
Diabetic under treatment 536 (15.4) 386 (11.1) 237 (14.8) 169 (10.5) 299 (15.9) 217 (11.5)
Diabetic not under treatment 105 (3.0) 37 (1.1) 39 (2.4) 18 (1.1) 66 (3.5) 19 (1.0)
Serum glucose, mmol/L 7.72±3.31 5.91±1.61 <0.001 7.67±3.46 5.86±1.49 <0.001 7.60±2.98 5.96±1.69 <0.001
Hypercholesterolaemia <0.001 <0.001 <0.001
Non-hypercholesterolaemic 2617 (75.2) 2506 (71.8) 1210 (75.6) 1139 (71.0) 1406 (74.6) 1367 (72.4)
Hypercholesterolaemic under
treatment with statins
587 (16.8) 437 (12.5) 276 (17.3) 207 (12.9) 311 (16.5) 230 (12.2)
Hypercholesterolaemic not
under treatment
280 (8.0) 549 (15.7) 113 (7.1) 258 (16.1) 167 (8.9) 291 (15.4)
Serum total cholesterol, mmol/L 4.74±1.21 5.42±1.09 <0.001 4.72±1.18 5.42±1.11 <0.001 4.77±1.22 5.42±1.09 <0.001
Current smoking 411 (11.8) 450 (12.9) 0.188 163 (10.2) 194 (12.1) 0.096 248 (13.2) 256 (13.6) 0.755
Alcohol, heavy intake 475 (14.3) 466 (13.3) 0.238 178 (11.9) 211 (13.2) 0.278 297 (16.4) 255 (13.5) 0.013
Antiplatelet agents 1138 (32.6) 510 (14.6) <0.001 553 (34.6) 236 (14.7) <0.001 585 (31.1) 274 (14.5) <0.001
Oral anticoagulants 432 (12.4) 30 (0.9) <0.001 240 (15.0) 14 (0.9) <0.001 192 (10.2) 16 (0.8) <0.001
ICH, intracerebral haemorrhage; TIA, transient ischaemic attack.
Table 2 Multivariable ORs for intracerebral haemorrhage by location
All ICH Lobar ICH Deep ICH
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age, years 1.004 (0.99 to 1.009) 0.100 1.00 (0.99 to 1.01) 0.302 1.00 (0.99 to 1.01) 0.264
Hypertension
Non-hypertensive 1 1 1
Hypertensive under treatment 1.55 (1.37 to 1.74) <0.001 1.23 (1.03 to 1.47) 0.018 1.86 (1.58 to 2.19) <0.001
Hypertensive not under treatment 9.46 (7.41 to 12.0) <0.001 6.43 (4.45 to 9.29) <0.001 12.51 (8.98 to 17.42) <0.001
Diabetes
Non-diabetic 1 1 1
Diabetic under treatment 1.18 (1.01 to 1.39) 0.035 1.15 (0.90 to 1.47) 0.249 1.19 (0.96 to 1.48) 0.100
Diabetic not under treatment 2.47 (1.63 to 3.74) <0.001 2.30 (1.23 to 4.30) 0.009 2.58 (1.47 to 4.53) 0.001
Cholesterolaemia
Non-hypercholesterolaemic 1 1 1
Hypercholesterolaemic under treatment with statins 0.79 (0.68 to 0.93) 0.006 0.85 (0.67 to 1.07) 0.184 0.75 (0.60 to 0.93) 0.011
Hypercholesterolaemic not under treatment 0.44 (0.37 to 0.52) <0.001 0.39 (0.30 to 0.52) <0.001 0.46 (0.37 to 0.58) <0.001
Alcohol, heavy intake 1.079 (0.92 to 1.26) 0.335 0.89 (0.69 to 1.13) 0.346 1.26 (1.03 to 1.55) 0.024
Current smoking 1.10 (0.94 to 1.30) 0.222 1.04 (0.81 to 1.35) 0.346 1.13 (0.91 to 1.40) 0.251
Antiplatelet agents 3.24 (2.83 to 3.70) <0.001 3.59 (2.94 to 4.37) <0.001 3.05 (2.54 to 3.66) <0.001
Oral anticoagulants 19.13 (13.08 to 27.98) <0.001 25.33 (13.98 to 42.34) <0.001 15.67 (9.26 to 26.49) <0.001
Multivariable model controlled for age, hypertension, diabetes mellitus, hypercholesterolaemia, current smoking, alcohol consumption and antithrombotic medications.
ICH, intracerebral haemorrhage.
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and statin use (Z) with covariates, we considered the ‘covariate
contribution’ (CC=the sum of the covariates, excluding X and
Z, multiplied by their corresponding logit coefﬁcient), as sug-
gested by Mitchell and Chen.9 This reﬂects the aggregate contri-
bution of covariates when the predicted probabilities of
outcome (Y) in the logistic model are represented in a two-
dimensional plot. In particular, the probability plot displays the
outcome probability Y as a function of the continuous variable
X and the binary variable Z for low (20th centile) and high
(80th entile) of CC. The threshold of statistical signiﬁcance was
set at p<0.05 for all analyses. Data were analysed using SPSS
for Windows V.16.0 (SPSS Inc, Chicago, Illinois, USA) package
(http://www.spss.com) and our codes in R.10
RESULTS
A total of 3492 patients with ICH (mean age, 73.0±12.7 years;
males, 56.6%) and 3492 control subjects (mean age, 70.6
±10.5 years; males, 56.6%) were eligible for inclusion in the
present study. All participants were Caucasian. Based on the
location of the haematoma, 1604 (45.9%) patients were cate-
gorised as lobar ICH cases, while 1888 (54.1%) were consid-
ered deep (non-lobar) ICH cases. Demographic and baseline
clinical characteristics of the study group are summarised in
table 1, stratiﬁed by haematoma location. Compared to control
subjects, cases were more likely to have a pre-ICH history of
coronary artery disease, hypertension and diabetes, and to be
prescribed antithrombotic medications. Their mean serum
glucose levels, as well as systolic and diastolic BP values at the
time of presentation were also higher. Conversely, they were less
likely to have a history of hypercholesterolaemia and their mean
serum total cholesterol concentration was lower.
Table 2 summarises the associations between selected predis-
posing factors and the risk of ICH. The effect of hypertension,
diabetes mellitus and heavy alcohol consumption in increasing
the risk of cerebral bleeding was prominent in non-lobar
regions, whereas the use of antithrombotic medications was
more strongly associated with lobar location of the haematoma.
In contrast, we did not detect any association between current
smoking and ICH, regardless of haemorrhage location. Of note,
the protective effect of hypercholesterolaemia was apparently
attenuated by statin use, especially in the subgroup of patients
with lobar ICH.
The AIC index and BIC index signed the ‘total serum
cholesterol-statin use complete interaction model’ (see online
supplementary ﬁgure S1, model 8) as the best in predicting the
effect of statins and total serum cholesterol levels on ICH risk
(see online supplementary table S1 and S2). Effects estimates for
the interaction between statin use and total serum cholesterol
levels, re-expressed as ORs, are displayed in table 3. The inter-
action between total serum cholesterol levels and statin use for
the risk of haemorrhage was statistically signiﬁcant (IOR, 1.09;
95% CI 1.05 to 1.12 for ICH regardless of haemorrhage loca-
tion; IOR, 1.13; 95% CI 1.08 to 1.19 for strictly lobar ICH;
IOR, 1.07; 95% CI 1.01 to 1.13 for deep ICH). Therefore, the
effects of cholesterol and statins were not conditionally inde-
pendent, but average effects. Overall, increasing levels of total
serum cholesterol were associated with a decreased risk of ICH
within statin strata (average OR, 0.87; 95% CI 0.86 to 0.88 for
every increase of 0.26 mmol/L of total serum cholesterol con-
centrations), an average effect that did not change substantially
according to the location of cerebral haematoma (OR, 0.86;
95% CI 0.84 to 0.88 for strictly lobar ICH; OR, 0.88; 95% CI
0.86 to 0.90 for deep ICH). Conversely, statin use was asso-
ciated with an increased risk of ICH at the average level of total
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serum cholesterol (5.7 mmol/L: OR, 1.54; 95% CI 1.31 to 1.81
for ICH regardless of haemorrhage location; OR, 1.58; 95% CI
1.28 to 1.96 for strictly lobar ICH; OR, 1.44; 95% CI 1.14 to
1.82 for deep ICH). These ﬁndings were not substantially
affected by adjustment for covariates, except for the effect of
statins on the risk of ICH, which was strongly attenuated and
became non-signiﬁcant in the multivariable model. Statin use
resulted in a less dramatic change in the risk of cerebral bleeding
across cholesterol values compared to non-statin use.
Statin use, in particular, turned out to reduce the protective
effect of total serum cholesterol against ICH, especially in
strictly lobar brain regions more than in non-lobar ones
(ﬁgure 1 and see online supplementary ﬁgure S2). We observed
a direct, linear, slightly increased predicted probability of ICH
with increasing serum concentrations of total cholesterol in the
subgroup of patients under treatment with statins, an effect that
was prominent in the subgroup of patients with haemorrhage
located in lobar brain regions compared to the whole cohort or
to the subgroup of patients with non-lobar ICH.
DISCUSSION
The question of whether cholesterol-lowering drugs might be
involved in the relationship between serum lipids, including
cholesterol and ICH, has been a matter of long debate. In par-
ticular, it is still unclear whether statin use may confer an
increased risk of cerebral bleeding. The results of our study
provide, therefore, further information on this theme and novel
insights into the role of serum lipids in the aetiology of ICH.
In line with a number of prior reports,1 as well as with the
results of in vitro and animal studies,11–13 we conﬁrmed that total
serum cholesterol concentrations are inversely associated with the
risk of ICH. Owing to the observational nature of our analysis,
however, the extent to which serum cholesterol can be judged
causal in the occurrence of ICH is difﬁcult to assess, and it could
be that low cholesterol levels might simply be an epiphenomenon
of the individual propensity to cerebral haemorrhage. Although
we cannot deﬁnitively rule out this alternative interpretation, the
dose-dependent relationship we found (approximately 12%
decreased risk of ICH for every increase of 0.26 mmol/L in total
serum cholesterol concentration) might be considered, however,
an argument in favour of the hypothesis of a pathogenic link
between serum cholesterol and cerebral haemorrhage.
Our ﬁndings also suggest that statin use before the index event
might be related to intracerebral bleeding. A number of previous
studies have highlighted the fact that statins, besides their effects
as cholesterol-lowering agents, exhibit a wide range of
antithrombotic properties, as a consequence of their modulatory
effects on proﬁbrinolytic mechanisms, blood coagulation cascade
and platelet functions.5 11 14 These effects could theoretically
account for an increased risk of bleeding complications. Based on
our data, the contribution of statins to the risk of cerebral bleed-
ing might occur, at least in part, through their effect on serum
total cholesterol levels. In particular, the use of statins seems to
reduce the strength of the inverse association between cholesterol
and ICH, so that any protective inﬂuence of hypercholesterol-
aemia might be attenuated by the cholesterol-lowering effect of
these agents. These ﬁndings, indirectly, reinforce the assumption
that total cholesterol might be related to the occurrence of brain
haemorrhage, and make the inﬂuence of confounders, such as
general medical or nutritional status, unlikely.15 On the other
hand, however, they are at odds with the results of previous
meta-analyses of statin therapy, which found no increased risk
of haemorrhagic stroke in participants taking these medica-
tions.16–19 In particular, the inconsistency between the results
from randomised clinical trials18 19 and our ﬁndings is substan-
tial, and calls for further investigation on how exactly cholesterol
and statins affect stroke risk in order to explain this striking dis-
crepancy. It should be noted, in this regard, that most of the pre-
vious studies on this topic were based on conventional regression
models that allow quantiﬁcation of the strength of the independ-
ent association of each factor (ie, statins use or cholesterol level)
with disease risk but do not allow evaluation of the interaction’s
effects among these factors. What distinguishes our study from
others is the application of a regression model that is able to
explore and quantify the cholesterol-statin interactions and illus-
trate how these interactions inﬂuence outcome.
Another ﬁnding from our data is the differential patterns of
association, the strongest effect of statins being detected in the
subgroup of patients with strictly lobar haemorrhage, likely
related to cerebral amyloid angiopathy.20 In agreement with our
ﬁndings, statin therapy has been associated with an increased
prevalence and severity of cerebral microbleeds in cortical-
subcortical brain regions,21 22 as well as with a higher propen-
sity for lobar ICH in a recent epidemiological study with the
same case–control design as ours.23 This supports the hypoth-
esis of a different susceptibility of cerebral small vessels to the
effect of serum lipids and statins.
The MUCH-Italy collaborative study differs from previous epi-
demiological analyses on this topic in several ways that increase
its reliability and precision: it is large, involving more than twice
the number of participants included in previous observational
studies with the same design; it is based on rigorous case–control
Figure 1 Predicted probability (risk) of overall ICH (A), lobar ICH (B) and deep ICH (C), for total cholesterol and statin use. ICH, intracerebral
haemorrhage.
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matching and racial homogeneity; fasting total serum cholesterol
levels are available for most of the participants, which implicates
the ability to perform adequate interaction analyses; and it has
the advantages of hospital-based recruitment, including detailed
and standardised data collection with little missing information,
and complete radiological data allowing exploration of the effect
of confounders on the cholesterol–statins–ICH relationship.
Nevertheless, we are aware of several limitations. We did not
control for statin dosing, duration of treatment or compliance,
because these data were not collected. The same is true for the
lack of cholesterol fractions, such as high-density lipoprotein and
low-density lipoprotein concentrations, as well as for the absence
of repeated measures of cholesterol, which does not allow the
ruling out of intraindividual ﬂuctuations in serum levels over
time. Another caveat is the possibility that vascular disease can
itself directly or indirectly affect blood cholesterol concentration
because of the inﬂuence that the acute phase reaction to ICH
might have had on admission levels in the group of cases.
Although these drawbacks are noteworthy, we believe they do
not alter the obvious clinical implication of our ﬁndings.
CONCLUSIONS
Although we cannot dispute the fact that the potential risk of
ICH associated with statin use, if any, is unlikely to overshadow
the large beneﬁts conferred by lipid-lowering medications in
reducing cardiovascular events, including ischaemic stroke,2 clin-
icians should carefully consider bleeding susceptibility when
prescribing statin therapy targeting reduced cardiovascular risk.
Identiﬁcation of those statin users who are more prone to
develop this complication will be the goal of future research.
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